AFRICA – 03 January 2017 – GlaxoSmithKline today announced the closure of one of its series of agreements with Aspen Pharmacare Holdings Limited (JSE: APN) and certain of its subsidiaries (“Aspen”), which were the subject of announcements by both companies on 12 September 2016. GSK and Aspen have terminated their collaboration in Sub-Saharan Africa and […]
November 17, 2016 – KENILWORTH, N.J.–(BUSINESS WIRE)–The Merck Foundation (Foundation) announced today the launch of a new initiative, Bridging the Gap: Reducing Disparities in Diabetes Care (Bridging the Gap), to improve access to high-quality diabetes care and reduce health disparities for vulnerable and underserved populations in the United States. With $10 million in funding from the […]
London – 16 November 2016 – GlaxoSmithKline plc (LSE/NYSE: GSK) today announced results from two pivotal phase III studies evaluating subcutaneous sirukumab, a human anti-interleukin (IL)-6 monoclonal antibody in development for the treatment of adults with moderately to severely active rheumatoid arthritis (RA). The first study (SIRROUND-T), in patients who were refractory to or intolerant to […]
FOSTER CITY, Calif.–(BUSINESS WIRE)–Nov. 16, 2016– Gilead Sciences, Inc. (Nasdaq: GILD) today announced top-line results from two Phase 3 clinical trials (SIMPLIFY 1 and 2) evaluating momelotinib, an investigational inhibitor of Janus kinase (JAK) compared to ruxolitinib or best alternative therapy (BAT) in patients with myelofibrosis. The SIMPLIFY-1 study achieved its pre-specified primary endpoint of […]
FOSTER CITY, Calif.–(BUSINESS WIRE)–Nov. 16, 2016– Gilead Sciences, Inc. (NASDAQ: GILD) today announced the promotion of James R. Meyers to Executive Vice President, Worldwide Commercial Operations, with responsibility for commercial operations in North America, Europe and Japan. Mr. Meyers will become an officer of the company and member of Gilead’s senior leadership team. Mr. Meyers […]
Research network of 21 academic centers from around the world to access and share technology, data and expertise to advance the science of cancer immunotherapy Roche will invest up to 100 million Swiss Francs to support basic and clinical research collaborations within the imCORE Network Basel, 15 November 2016 – Roche (SIX: RO, ROG; OTCQX: […]
Cooperative Research and Development Agreement (CRADA) assesses OX40 agonist, utomilumab and avelumab immuno-oncology assets alone and in various combinations November 14, 2016 – Pfizer Inc. (NYSE:PFE) today announced that it has entered into a Cooperative Research and Development Agreement (CRADA) with the National Cancer Institute (NCI), part of the National Institutes of Health (NIH). As part […]
Phase 2 Data Presentations at The Liver Meeting ® Detail SVR12 Rates from Two Studies as Well as SVR8 Rates in Patients for Whom Direct-Acting Antiviral Treatment Previously Failed November 13, 2016 – KENILWORTH, N.J.–(BUSINESS WIRE)–Merck (NYSE:MRK), known as MSD outside of the United States and Canada, today announced the presentation of results from three […]
Patients Taking Pfizer’s Celebrex (celecoxib) Experienced Fewer Gastrointestinal Events As Compared to Prescription Doses of Ibuprofen and Naproxen Study Findings Dispel Long Standing Perceptions of Excess Cardiovascular Risk Associated With Long Term Use Of Celebrex Results of PRECISION Study Presented at the Annual Meeting of the American Heart Association in New Orleans Provide Important Information […]
Merck Announces Presentation of New Findings for ZEPATIER™ (Elbasvir and Grazoprevir) in Patients with Chronic Hepatitis C at The Liver Meeting® November 12, 2016 – KENILWORTH, N.J.–(BUSINESS WIRE)–Merck (NYSE:MRK), known as MSD outside of the United States and Canada, today announced results from multiple analyses at The Liver Meeting® 2016, which provide additional evidence supporting the […]